CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BackgroundWe conducted a phase I clinical trial that infused CCR5 gene-edited CD4+ T cells to determine how these T cells can better enable HIV cure strategies.MethodsThe aim of trial was to develop RNA-based approaches to deliver zinc finger nuclease (ZFN), evaluate the effect of CCR5 gene-edited CD4+ T cells on the HIV-specific T cell response, test the ability of infused CCR5 gene-edited T cells to delay viral rebound during analytical treatment interruption, and determine whether individuals heterozygous for CCR5 Δ32 preferentially benefit. We enrolled 14 individuals living with HIV whose viral load was well controlled by antiretroviral therapy (ART). We measured the time to viral rebound after ART withdrawal, the persistence of CCR5-edited CD4+ T cells, and whether infusion of 10 billion CCR5-edited CD4+ T cells augmented the HIV-specific immune response.ResultsInfusion of the CD4+ T cells was well tolerated, with no serious adverse events. We observed a modest delay in the time to viral rebound relative to historical controls; however, 3 of the 14 individuals, 2 of whom were heterozygous for CCR5 Δ32, showed post-viral rebound control of viremia, before ultimately losing control of viral replication. Interestingly, only these individuals had substantial restoration of HIV-specific CD8+ T cell responses. We observed immune escape for 1 of these reinvigorated responses at viral recrudescence, illustrating a direct link between viral control and enhanced CD8+ T cell responses.ConclusionThese findings demonstrate how CCR5 gene-edited CD4+ T cell infusion could aid HIV cure strategies by augmenting preexisting HIV-specific immune responses.REGISTRATIONClinicalTrials.gov NCT02388594.FundingNIH funding (R01AI104400, UM1AI126620, U19AI149680, T32AI007632) was provided by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS). Sangamo Therapeutics also provided funding for these studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713 · cited 1×
“The use of adenovirus-based vectors has been associated with the formation of immune complexes, and this may be undesirable for use in HIV cure strategies (45, 46).”
BackgroundGene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
Self-citationEstablishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V., Lee, Y.-L., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1410 · Cited by 999 · cited 2×
“(37, 56) were each generated separately in the pIDTSmart vector (Inte-”
MethodSelf-citationA quantitative approach for measuring the reservoir of latent HIV-1 proviruses
Bruner, K. M., Wang, Z., Simonetti, F. R., Bender, A. M., Kwon, K. J., Sengupta, S., Fray, E. J., Beg, S. A., Antar, A. A. R., Jenike, K. M., et al. (2019) · Nature · doi:10.1038/s41586-019-0898-8 · Cited by 718
CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817426 · Cited by 454 · cited 1×
“Other gene-editing methods including CRISPR are also in development for HIV (44).”
MethodThe Toll-like receptor gene family is integrated into human DNA damage and p53 networks
Menendez, D., Shatz, M., Azzam, K., Garantziotis, S., Fessler, M. B., & Resnick, M. A. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001360 · Cited by 148
Maier, D. A., Brennan, A. L., Jiang, S., Binder-Scholl, G. K., Lee, G., Plesa, G., Zheng, Z., Cotte, J., Carpenito, C., Wood, T., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.172 · Cited by 126
Self-citationConway, A., Mendel, M., Kim, K., McGovern, K., Boyko, A., Zhang, L., Miller, J. C., DeKelver, R. C., Paschon, D. E., Mui, B. L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.003 · Cited by 95 · cited 1×
“New technologies to enhance the efficiency of gene editing while maintaining safety and specificity are emerging, including incorporation of ZFN structures into lipid nanoparticles (42) and improvement of ZFN structure algorithms that are able to generate ZFNs with a higher degree of precision, efficiency, and specifi…”
BackgroundSelf-citation
Cited by
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
Deeks, S. G., Archin, N., Cannon, P., Collins, S., Jones, R. B., de Jong, M. A. W. P., Lambotte, O., Lamplough, R., Ndung’u, T., Sugarman, J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01590-5 · Cited by 377
Self-citationTargeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
Mohamed, H., Gurrola, T., Berman, R., Collins, M., Sariyer, I. K., Nonnemacher, M. R., & Wigdahl, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816515 · Cited by 81
Current State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22
Dudek, A. M., Feist, W. N., Sasu, E. J., Luna, S. E., Ben-Efraim, K., Bak, R. O., Cepika, A.-M., & Porteus, M. H. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.03.002 · Cited by 19
Claiborne, D. T., Detwiler, Z., Docken, S. S., Borland, T. D., Cromer, D., Simkhovich, A., Ophinni, Y., Okawa, K., Bateson, T., Chen, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55873-3 · Cited by 16
Metadata
- Authors
- Tebas, P., Jadlowsky, J. K., Shaw, P. A., Tian, L., Esparza, E., Brennan, A. L., Kim, S., Naing, S. Y., Richardson, M. W., Vogel, A. N., Maldini, C. R., Kong, H., Liu, X., Lacey, S. F., Bauer, A. M., Mampe, F., Richman, L. P., Lee, G., Ando, D., Levine, B. L., Porter, D. L., Zhao, Y., Siegel, D. L., Bar, K. J., June, C. H., & Riley, J. L.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-04-01
- Volume
- 131
- Issue
- 7
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3126880691
- Cited by
- 99
- References
- 9
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. https://app.cochat.ai/papers/10.1172/jci144486
- The paper
- Tebas, P., Jadlowsky, J. K., Shaw, P. A., Tian, L., Esparza, E., Brennan, A. L., Kim, S., Naing, S. Y., Richardson, M. W., Vogel, A. N., Maldini, C. R., Kong, H., Liu, X., Lacey, S. F., Bauer, A. M., Mampe, F., Richman, L. P., Lee, G., Ando, D., . . . Riley, J. L. (2021). CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. Journal of Clinical Investigation. https://doi.org/10.1172/jci144486
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.